FDA considers a pathway for individualized gene-editing therapies

The FDA’s draft Individualized Feature Space framework could let related mutation-specific editing products be covered within one application, potentially easing development for ultra-rare diseases. It is not final guidance; public feedback and eventual evidence and implementation requirements will shape its impact. Separate finalized potency guidance adds manufacturing-quality expectations relevant to gene therapies.